A Phase 1/2 Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Phase of Trial: Phase I/II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Ibrutinib (Primary) ; Ulocuplumab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 23 Oct 2017 Status changed from not yet recruiting to recruiting.
- 05 Sep 2017 Planned initiation date changed from 31 Jul 2017 to 30 Sep 2017.
- 24 Jul 2017 New trial record